<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pegvisomant</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00082</strong>&#160; (BIOD00044, BTD00044)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Pegvisomant is a highly selective growth hormone (GH) receptor antagonist.  It is used to treat acromegaly.  Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (<span class="caps">IGF</span>-1), which is the main mediator of growth hormone activity.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00082.png?1266600380"><img alt="Db00082" src="/system/protein_structures/thumb/DB00082.png?1266600380"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>990</sub>H<sub>1532</sub>N<sub>262</sub>O<sub>300</sub>S<sub>7</sub></td></tr><tr><th>Protein average weight</th><td>22129.0000</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;DB00082 sequence
FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPT
PSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEG
IQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIV
QCRSVEGSCGF</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00082/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>GH</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>GH-N</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Growth hormone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Growth hormone 1</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pituitary growth hormone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Somatotropin precursor</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Somavert</td><td>Pfizer Inc</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hormone-replacement-agents">Hormone Replacement Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>218620-50-9</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.</td></tr><tr><th>Pharmacodynamics</th><td>Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.</td></tr><tr><th>Mechanism of action</th><td>Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>7 L</li>
</ul></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>~6 days</td></tr><tr><th>Clearance</th><td><ul>
	<li>36 &#8211; 28 mL/h [SC doses ranging from 10 to 20 mg/day]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pharmacia and upjohn co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Subcutaneous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Somavert 20 mg vial</td><td>208.38USD</td><td>vial</td></tr><tr><td>Somavert 15 mg vial</td><td>156.29USD</td><td>vial</td></tr><tr><td>Somavert 10 mg vial</td><td>104.18USD</td><td>vial</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5849535</td><td>1997-03-25</td><td>2017-03-25</td></tr><tr><td>United States</td><td>5350836</td><td>1994-09-27</td><td>2011-09-27</td></tr><tr><td>Canada</td><td>2230492</td><td>2009-05-26</td><td>2016-09-20</td></tr><tr><td>Canada</td><td>2102129</td><td>2003-04-01</td><td>2012-05-01</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>76 &#176;C at pH 3.5</td><td>Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998)</td></tr><tr><td>hydrophobicity</td><td>-0.411</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>isoelectric point</td><td>5.27</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Mandayam J. Narasimhan, John A. Anderson, &#8220;Process for the large scale production of human growth hormone by serial secondary suspension culture.&#8221; U.S. Patent US4124448, issued January, 1963.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4124448&amp;tbm=pts" target="_blank">US4124448 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>UniProt</td><td><a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P58756" target="_blank">P58756 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Genbank</td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=AF374232" target="_blank">AF374232 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164749630" target="_blank">PA164749630 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2272199" target="_blank">2272199 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/somavert.htm" target="_blank">http://www.rxlist.com/cgi/generic3/somavert.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/pegvisomant.html" target="_blank">http://www.drugs.com/cdi/pegvisomant.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>H01AX01<ul class="atc-drug-tree"><li><a href="/atc/H#H">H &#8212; SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</a></li><li><a href="/atc/H01#H01">H01 &#8212; PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</a></li><li><a href="/atc/H01A#H01A">H01A &#8212; ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</a></li><li><a href="/atc/H01AX#H01AX">H01AX &#8212; Other anterior pituitary lobe hormones and analogues</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>68:30.08</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1HWG" target="_blank">1HWG <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00082.pdf?1265922814">show</a>(864 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01551">Dihydrocodeine</a></td><td>Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>